Aviscumine
Small moleculeexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00658437)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- RibosomeINHIBITOR
Ribosome inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108170 ↗
Also known as
- cy-503
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00932724 | Phase 2 | Jul 1, 2009 | ClinAssess GmbH, Cytavis Biopharma GmbH, Humboldt University, J. W. Goethe University, Medical University Innsbruck |
| NCT00658437 | Phase 2 | Apr 1, 2008 | Cytavis Biopharma GmbH, Elbe Klinikum Buxtehude, Germany |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cytavis Biopharma GmbH | For profit | 2 | 2 | 1 | 2008 |
| ClinAssess GmbH | For profit | 1 | 0 | 1 | 2009 |
| Elbe Klinikum Buxtehude, Germany | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Humboldt University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| J. W. Goethe University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Medical University Innsbruck | Academic/Hospital | 1 | 0 | 1 | 2009 |
6 organizations
Page 1 / 1